Dedifferentiated Liposarcoma (DDLPS) Explained

What Is Dedifferentiated Liposarcoma?

Dedifferentiated liposarcoma (DDLPS) is a high-grade soft tissue sarcoma that develops out of a well-differentiated liposarcoma — the slow-growing, low-grade form of fat-cell cancer also called an atypical lipomatous tumour. "Dedifferentiation" is the term pathologists use when part of a calm, well-organised tumour switches into a far more aggressive, disorganised one. The result is a single mass that contains two different tumours side by side: a mature, fat-like well-differentiated zone, and a high-grade zone whose cells no longer look like fat at all.

This dual nature is the key to understanding the subtype. The well-differentiated part rarely spreads, but the dedifferentiated part behaves like other aggressive sarcomas — it can grow quickly, invade nearby structures, and occasionally seed to the lungs. DDLPS sits at the more dangerous end of the liposarcoma family, which also includes well-differentiated, myxoid, and pleomorphic types. Because it so often begins in the abdomen, it is closely related to retroperitoneal liposarcoma — in fact the retroperitoneum (the space behind the abdominal organs) is its single most common home.

You may see DDLPS described in your report as "high grade liposarcoma" or "dedifferentiated lps"; these mean the same thing. For a wider view of how all the subtypes fit together, the sarcoma — overview hub maps every soft tissue sarcoma type, while details on local care are on our sarcoma treatment in Hyderabad page.

Dedifferentiated vs Well-Differentiated Liposarcoma — What's the Difference?

The two are intimately linked: dedifferentiated liposarcoma almost always arises within or from a well-differentiated liposarcoma (WDLPS). Think of WDLPS as the starting point and DDLPS as what happens when a portion of it transforms. Understanding the contrast helps make sense of why DDLPS is treated more urgently.

The practical message for a subtype researcher: a report saying "well-differentiated liposarcoma with a focus of dedifferentiation" is describing a tumour that must be treated as the high-grade tumour it now contains. The dedifferentiated component sets the grade, the urgency, and the treatment plan — not the larger, calmer fatty part around it.

Where Does It Occur and What Are the Symptoms?

Dedifferentiated liposarcoma most commonly arises in the retroperitoneum, the deep space behind the abdominal organs. Because there is so much room there, a tumour can grow to a very large size — sometimes filling much of one side of the abdomen — before causing any symptoms at all. When symptoms do appear, they are usually pressure effects rather than pain:

• A gradually enlarging, painless abdominal swelling or a sense of fullness that does not settle
• Early satiety — feeling full after only a small meal because the mass presses on the stomach or bowel
• Vague back, flank or abdominal discomfort as the tumour stretches surrounding tissues
• A deep, firm lump in the thigh, limb or trunk when DDLPS occurs outside the abdomen
• A long-standing lump that suddenly grows faster — a classic sign of dedifferentiation within an older tumour

The most important takeaway is that DDLPS is usually painless in its early phase, which is exactly why it is so often found late. Any deep, enlarging mass — in the abdomen or a limb — should be imaged and biopsied rather than watched, because the difference between a benign fatty lump and a dedifferentiated liposarcoma cannot be judged by feel alone.

How Dedifferentiated Liposarcoma Is Diagnosed and Graded

Confirming DDLPS is a careful, stepwise process. Because it can be mistaken for both benign fatty lumps and for other high-grade sarcomas, the diagnosis depends on combining imaging, an expert biopsy, and molecular testing — not on any single test alone.

Step 1 — Imaging With MRI or CT

A contrast-enhanced MRI (for limb tumours) or CT (for abdominal tumours) maps the mass and looks for the tell-tale pattern of DDLPS: a largely fatty tumour containing one or more solid, non-fatty nodules. That solid component within an otherwise fatty mass is the radiological signature of dedifferentiation and tells the radiologist where the high-grade tissue lies. Imaging also defines the tumour's relationship to vital structures, which decides whether complete removal is possible.

Step 2 — Image-Guided Core Needle Biopsy

A core needle biopsy is taken — ideally targeting the solid, non-fatty area seen on imaging, because that is where the dedifferentiated cells are. The biopsy track is planned so it can be removed with the tumour at surgery. An open or excisional biopsy of a suspected liposarcoma is avoided, as it risks spreading the tumour.

Step 3 — MDM2 / CDK4 Molecular Confirmation

This is the step that defines the subtype. Both well-differentiated and dedifferentiated liposarcoma carry amplification of the MDM2 gene (and usually CDK4) on chromosome 12. Testing for MDM2 — by FISH or immunohistochemistry — confirms the tumour is truly a liposarcoma and not an undifferentiated pleomorphic sarcoma, which can look identical under the microscope. Getting this right matters, because it changes how the cancer is staged, treated and followed up.

Step 4 — Grading and Staging

DDLPS is graded using the FNCLCC system, which scores how abnormal the cells look (differentiation), how fast they divide (mitotic count), and how much dead tissue is present (necrosis). The dedifferentiated component is, by definition, intermediate-to-high grade (grade 2 or 3). A chest CT is then done to check the lungs, the most common site of spread, completing the stage.

How Dedifferentiated Liposarcoma Is Treated

Treatment is decided by a multidisciplinary tumour board and tailored to where the tumour is, its grade, and whether it can be completely removed. For DDLPS, surgery does the heavy lifting:

Because the dedifferentiated component can recur locally even after a good operation, long-term surveillance with periodic imaging is an essential part of the plan. Recurrence is most common in the first few years, which is why follow-up is structured and not left to chance.

Outlook and Prognosis for DDLPS

The outlook for dedifferentiated liposarcoma depends on several factors that a subtype researcher will want to understand together rather than in isolation. The most important are whether the tumour can be completely removed, its location, its grade, and the extent of the dedifferentiated component.

The single biggest driver of long-term outcome is a complete, margin-clear resection. Where the whole tumour is removed, the prognosis is meaningfully better than where disease is left behind. Location matters too: limb DDLPS is often more straightforward to clear than retroperitoneal disease, where the tumour's size and proximity to vital organs can make a clean margin harder to achieve — which is one reason it tends to recur locally over time. Distant spread to the lungs occurs in a minority of patients and is influenced by the grade and the size of the high-grade component.

Two points give grounds for measured optimism. First, the well-differentiated part of the tumour rarely spreads, so the threat is largely from the dedifferentiated zone, which surgery targets directly. Second, modern, structured surveillance catches local recurrences early, when they are most treatable. Numbers quoted in studies are population averages and cannot predict any one person's course — your own outlook depends on your specific tumour, which is exactly what a tumour board assessment is designed to clarify.

Indicative Cost in Hyderabad

Costs are indicative. A personalised estimate is provided after your CION consultation. EMI options and cashless support through major TPAs, Aarogyasri, CGHS, ECHS & ESI are available for eligible patients.

Why Patients Choose CION for Liposarcoma Care

Dedifferentiated liposarcoma needs a team that can confirm the subtype precisely and plan a complete resection. Here is why patients trust CION.

Understand Your Liposarcoma — Then Act on It

Dedifferentiated liposarcoma is most curable when it is confirmed precisely and removed completely the first time. If you are researching the subtype for yourself or a loved one, talk to a sarcoma specialist who can explain exactly what your report means.